Oncolytic viruses (OVs) as one promising antitumor methods have made important
contributions to tumor immunotherapy, which arouse increasing attention. They provide the …

Resistance to cancer therapies has been a commonly observed phenomenon in clinical
practice, which is one of the major causes of treatment failure and poor patient survival. The …

Cellular and stromal components including tumor cells, immune cells, mesenchymal cells,
cancer-linked fibroblasts, and extracellular matrix, constituent tumor microenvironment …

Oncolytic virotherapy holds promise for cancer treatment, but the factors determining its
oncolytic activity remain unclear. Neutrophil extracellular traps (NETs) are associated with …

Cancer Immunotherapy relies on harnessing a patient's immune system to fine-tune specific
anti-tumor responses and ultimately eradicate cancer. Among diverse therapeutic …

Immuno-oncology has traditionally focused on the cellular arm of the adaptive immune
response, while attributing tumor-promoting activity to humoral responses in tumor-bearing …

Introduction Clinical trials of personalized cancer vaccines have shown that on-demand
therapies that are manufactured for each patient, result in activated T cell responses against …

The determination of transcriptome profiles that mediate immune therapy in cancer remains
a major clinical and biological challenge. Despite responses induced by immune-check …

Extracellular vesicles (EVs), especially exosomes, have been reported to play essential
roles as extracellular messengers by transporting goods in various diseases, while their …

Small extracellular vesicles (SEV) have attracted much attention both as mediators of
intercellular communication and as drug delivery systems. In addition, recent studies have …